22Aug 2017

RISK OF COLORECTAL CANCER AND CLOTTING FACTOR GENE POLYMORPHISMS IN MOROCCAN POPULATION.

  • A PhD student of Centre of Doctoral study in health science-Doctoral training in genetics and molecular pathology -Laboratory of Genetics and Molecular Pathology, Medical School, University Hassan II, Casablanca BP 9154,Morocco.
  • General Surgery Department III, Ibn Rochd University Hospital Center, Casablanca BP 20102, Morocco.
  • Laboratory of Medical Genetics and Molecular Pathology, Faculty of Medicine and Pharmacy, Hassan II University, Casablanca, Morocco.
Crossref Cited-by Linking logo
  • Abstract
  • Keywords
  • References
  • Cite This Article as
  • Corresponding Author

Background: Venous thrombosis has been described as a common complication for cancer patients. The association between clotting factor gene polymorphisms and the risk of colorectal cancer has been evidenced. The aim of the present study was to investigate the association of G20210A factor II prothrombin (FII) and factor V Leiden ( FVL) G1691A with the risk of colorectal cancer(CRC).Methods and results. Genotyping of FVL and G20210A FII was performed using the polymerase chain reaction restriction fragment length polymorphism method on a sample of 76 patients with CRC as well as 182 controls. No significant difference in FVL gene variations was observed between cases and controls. However, with regard to the G20210A FII , the homozygous mutated genotype AA was associated with an increased risk of CRC. A significant association between the G20210A FII mutation and the risk of CRC was identified using recessive (OR=57.63, 95% CI: 3.33-997.26, P=0.0053), dominant (OR=27.87, 95% CI: 12.67 -61.28, P<0, 0001) and additive (OR=21.24, 95% CI: 10.45-43.16, P<0, 0001) models. No statistical difference was observed in parameters such as sex, age and positive family history for cancer .Conclusion. Our results did not support an effect of FVL gene on CRC risk and suggested that the G20210A FII prothrombin gene variant may be a risk factor for CRC in Moroccan population.

  1. Chew H, Wun T, Harvey D et al. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med 2006;166(4):458-64
  2. Sorensen T,? Mellemkjaer? L,? Olsen? J,? et al.? Prognosis? of? cancers? associated? with venous thromboembolism. N Engl J Med 2000; 343:1846-50
  3. Sauve C, Boffa M, Meyer G et al. Maladie thromboembolique veineuse et cancer. Rev Med Interne 2000;21:266-77. 2000
  4. Milsom C, Yu J, Mackman N et al. Tissue Factor regulation by Epidermal Growth Factor Receptor and epithelial-to mesenchymal transitions: Effect on tumor initiation and angiogenesis. Cancer Res 2008;68:10068?76
  5. Rickles FR, Falanga A. Activation of clotting factors in cancer.Cancer Treat Res 2009;148:31?41.
  6. Kuderer? NM,? Ortel? TL,? Francis? ? Impact? of? venous? throm-boembolism and anticoagulation on cancer and cancer survival.J Clin Oncol 2009;27:4902?11.
  7. Fernandez P, Patierno S, Rickles F. Tissue factor and fibrin in tumor angiogenesis.Semin Thromb Hemost 2004; 30: 31-44
  8. MaY, He X, Wang H et al. Interaction of coagulation factors and tumor-associated macrophages mediates migration and invasion of gastric cancer. Cancer Sci 2011;102: 336-42
  9. Cancer LSAa. Cancer Registry of the Greater Casablanca. 2016:69
  10. Giovannucci E, Willett WC. Dietary factors and risk of colon cancer. Annals of medicine. 1994 Dec;26(6):443-52. PubMed PMID: 7695871. Epub 1994/12/01. Eng
  11. van Duijnhoven? EM,? Lustermans? FA,? van Wersch? JW:? Evaluation? of? the? coagulation/fibrinolysis balance in patients with colorectal cancer. Haemostasis?? 1993?? ; 23:168?172.
  12. Edwards CM, Warren J, Armstrong L, Donnelly?? PK:? D-dimer:? A?? useful?? marker?? of? disease stage in surgery for colorectal cancer. Br J Surg1993;80:1404?1405.
  13. Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH: Mutation in blood coagulation factor? V? associated? with? resistance? to activated protein C. Nature 1994;369:64?67.
  14. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM: A? common? genetic? variation? in? the? 3?-untranslated region of the prothrombin gene is associated? with? elevated? plasma? prothrombinlevels? and? an? increase? in? venous? Blood 1996;88:3698?3703.
  15. M?zsik G, Rumi G,? D?m?t?r A , et al: Involvement of serum retinoids and Leiden mutation in patients with esophageal, gastric, liver, pancreatic, and colorectal cancers in Hungary World J Gastroenterol 11: 7646? 7650,2005 CrossRef, Medline ,
  16. Miller GJ, Bauer KA, Howarth DJ, Cooper JA, Humphries SE, Rosenberg RD. Increased incidence of neoplasia ofthe digestive tract in men with persistent activation of the coagulant pathway. J Thromb Haemost 2004; 2: 2107-2114
  17. Pihusch R, Danzl G, Scholz M, Harich D, Pihusch M, LohseP, Hiller E. Impact of thrombophilic gene mutations on thrombosis risk in patients with gastrointestinal carcinoma.Cancer 2002; 94: 3120-3126.
  18. Miller SA,? Dykes DD, and Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Research, vol. 16, no. 3, article 1215, 1988
  19. Huber S, McMaster KJ, Voelkerding KV. Analytical evaluation of primer engineered multiplex polymerase chain reaction-restriction fragment length polymorphism for detection of factor V Leiden and prothrombin G20210A. J Mol Diagn. 2000;2:153?157. doi: 10.1016/S1525-1578(10)60631-9.
  20. Danneberg J, Abbes AP, Bruggeman BJ, Engel H, Gerrits J and Martens A: Reliable genotyping of the G‑20210‑A mutation of coagulation factor II (prothrombin). Clin Chem 44: 349‑351, 1998.
  21. Hmimech W, Diakite B, Idrissi HH, Hamzi K, Korchi F, Baghdadi D, Habbal R, Nadifi S: G2691A and C2491T mutations of factor V gene and pre-disposition to myocardial infarction in Morocco. Biomedical reports 2016, 5(5):618-622.
  22. Vossen CY, Hoffmeister M, Chang-Claude JC, Rosendaal FR and Brenner H: Clotting factor gene polymorphisms and colorectal cancer risk. J Clin Oncol 29: 1722-1727, 2011
  23. Paspatis GA, Sfyridaki A, Papanikolaou N, Triantafyllou K, Livadiotaki A, Kapsoritakis A, Lydataki N. Resistance to activated protein C, factor V leiden and the prothrombin G20210A variant in patients with colorectal cancer. Pathophysiol Haemost Thromb. 2002;32:2?7.
  24. Ozkan M, Sivgin S, Kocyigit I, et al: Do thrombophilic gene mutations have? a? role? on? thromboembolic? events? in? cancer? patients? Asia Pac J Clin Oncol 8: e34-e41, 2012
  25. Arruda VR, Annichino‑Bizzacchi JM, Gon?alves MS and Costa FF: Prevalence of the prothrombin gene variant (nt20210A) in venous thrombosis and arterial disease. Thromb Haemost 78: 1430‑1433, 1997.
  26. Lane DA, Philippou H and Huntington JA: Directing thrombin. Blood 106: 2605‑2612, 2005.

[Imane Baghad, Driss Erguibi, Farid Chehab and Sellama Nadifi. (2017); RISK OF COLORECTAL CANCER AND CLOTTING FACTOR GENE POLYMORPHISMS IN MOROCCAN POPULATION. Int. J. of Adv. Res. 5 (Aug). 1141-1146] (ISSN 2320-5407). www.journalijar.com

BAGHAD Imane
A PhD student of Centre of Doctoral study in health science-Doctoral training in genetics and molecular pathology -Laboratory of Genetics and Molecular Pathology, Medical School, University Hassan II, Casablanca BP 9154,Morocco

DOI:

Article DOI: 10.21474/IJAR01/5166      
DOI URL: http://dx.doi.org/10.21474/IJAR01/5166

Download Full Paper

Download PDF No. of Downloads: 35 | No. of Views: 211